|
[1]HARDY T, OAKLEY F, ANSTEE QM, et al.Nonalcoholic fatty liver disease:pathogenesis and disease spectrum[J].Annu Rev Pathol, 2016, 11 (1) :451-496.
|
|
[2]DOWMAN JK, TOMLINSON JW, NEWSOME PN.Pathogenesis o non-alcoholic fatty liver disease[J].QJM, 2010, 103 (2) :69-70.
|
|
[3] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J].Hepatology, 2016, 64 (1) :73-84.
|
|
[4]WATANABE S, HASHIMOTO E, IKEJIMA K, et al.Evidencebased clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].J Gastroenterol, 2015, 50 (4) :364-377.
|
|
[5]WONG VW, CHAN WK, CHITTURI S, et al.The Asia-Pacific Working Party on nonalcoholic fatty liver disease guidelines 2017Part 1:definition, risk factors and assessment[J].J Gastroenterol Hepatol, 2017.[Epub ahead of print]
|
|
[6]BOUZIANAS DG, BOUZIANA SD, HATZITOLIOS AI.Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids[J].Nutr Rev, 2013, 71 (11) :753-771.
|
|
[7]XIN SL, XU KS.A new understanding of the pathogenesis of nonalcoholic fatty liver disease[J].J Clin Hepatol, 2017, 33 (8) :1581-1583. (in Chinese) 辛晟梁, 徐可树.非酒精性脂肪性肝病发病机制新认识[J].临床肝胆病杂志, 2017, 33 (8) :1581-1583.
|
|
[8]ZELBER-SAGI S, SALOMONE F, MLYNARSKY L.The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease:evidence and plausible mechanisms[J].Liver Int, 2017, 37 (7) :936-949.
|
|
[9]European Association for the Study of the Liver (EASL) ;European Association for the Study of Diabetes (EASD) ;European Association for the Study of Obesity (EASO) .EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease[J].J Hepatol, 2016, 64 (6) :1388-1402.
|
|
[10]NASKA A, TRICHOPOULOU A.Back to the future:the Mediterranean diet paradigm[J].Nutr Metab Cardiovasc Dis, 2014, 24 (3) :216-219.
|
|
[11]RATZIU V, GOODMAN Z, SANYAL A.Current efforts and trends in the treatment of NASH[J].J Hepatol, 2015, 62 (1) :s65-s75.
|
|
[12]van der HEIJDEN GJ, WANG ZJ, CHU ZD, et al.A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents[J].Obesity, 2010, 18 (2) :384-390.
|
|
[13]HALLSWORTH K, FATTAKHOVA G, HOLLINGSWORTH KG, et al.Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss[J].Gut, 2011, 60 (9) :1278-1283.
|
|
[14]SANYAL AJ, CHALASANI N, KOWDLEY KV, et al.Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J].NEngl J Med, 2010, 362 (18) :1675-1685.
|
|
[15]SOCHA P, HORVATH A, VAJRO P, et al.Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children:a systematic review[J].J Pediatr Gastroenterol Nutr, 2009, 48 (5) :587-596.
|
|
[16]RAKOSKI MO, SINGAL AG, ROGERS MA, et al.Meta-analysis:insulin sensitizers for the treatment of non-alcoholic steatohepatitis[J].Aliment Pharmacol Ther, 2010, 32 (10) :1211-1221.
|
|
[17]SHYANGDAN D, CLAR C, GHOURI N, et al.Insulin sensitisers in the treatment of non-alcoholic fatty liver disease:a systematic review[J].Health Technol Assess, 2011, 15 (38) :1-110.
|
|
[18]BOETTCHER E, CSAKO G, PUCINO F, et al.Meta-analysis:pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis[J].Aliment Pharmacol Ther, 2012, 35 (1) :66-75.
|
|
[19]LAVINE JE.Vitamin E treatment of nonalcoholic steatohepatitis in children:a pilot study[J].J Pediatr, 2000, 136 (6) :734-738.
|
|
[20]HASEGAWA T, YONEDA M, NAKAMURA K, et al.Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis:a pilot study[J].Aliment Pharmacol Ther, 2001, 15 (10) :1667-1672.
|
|
[21]MILLER ER 3rd, PASTOR-BARRIUSO R, DALAL D, et al.Meta-analysis:high-dosage vitamin E supplementation may increase all-cause mortality[J].Ann Intern Med, 2005, 142 (1) :37-46.
|
|
[22]BJELAKOVIC G, NIKOLOVA D, GLUUD C.Meta-Regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality:do we have evidence for lack of harm?[J].PLo S One, 2013, 8 (9) :e74558.
|
|
[23]SAMY W, HASSANIAN MA.Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin[J].Arab J Gastroenterol, 2011, 12 (2) :80-85.
|
|
[24]FOSTER T.Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease[J].Am J Gastroenterol, 2010, 106 (1) :71-77.
|
|
[25]YOKOHAMA S, YONEDA M, HANEDA M, et al.Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis[J].Hepatology, 2004, 40 (5) :1222-1225.
|
|
[26]GEORGESCU EF, IONESCU R, NICULESCU M, et al.Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis[J].World J Gastroenterol, 2009, 15 (8) :942-954.
|
|
[27]LIU H, LIU CC, BAO JF.Research advances inω-3 polyunsaturated fatty acids in treatment of nonalcoholic fatty liver disease[J].J Med Res, 2017, 46 (2) :20-22. (in Chinese) 刘慧, 刘晨晨, 包剑锋.ω-3多不饱和脂肪酸治疗非酒精性脂肪肝的研究进展[J].医学研究杂志, 2017, 46 (2) :20-22.
|
|
[28]JUMP DB.Fatty acid regulation of hepatic lipid metabolism[J].Curr Opin Clin Nutr Metab Care, 2011, 14 (2) :115-120.
|
|
[29]ALI AH, CAREY EJ, LINDOR KD.Recent advances in the development of farnesoid X receptor agonists[J].Ann Transl Med, 2015, 3 (1) :5.
|
|
[30]MCGETTIGAN BM, MCMAHAN RH, LUO Y, et al.Sevelamer improves steatohepatitis, inhibits liver and intestinal farnesoid X receptor (FXR) , and reverses innate immune dysregulation in a mouse model of non-alcoholic fatty liver disease[J].J Biol Chem, 2016, 291 (44) :23058-23067.
|
|
[31]KONG B, LUYENDYK JP, TAWFIK O, et al.Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet[J].JPharmacol Exp Ther, 2009, 328 (1) :116-122.
|
|
[32]CHEN L, YAO X, YOUNG A, et al.Inhibition of apical sodiumdependent bile acid transporter as a novel treatment for diabetes[J].Am J Physiol Endocrinol Metab, 2012, 302 (1) :e68-e76.
|
|
[33]RAO A, KOSTERS A, MELLS JE, et al.Inhibition of ileal bile acid uptake protects against non-alcoholic fatty liver disease in high fat diet-fed mice[J].Sci Transl Med, 2016, 8 (357) :357ra122.
|
|
[34]FRIEDMAN S, SANYAL A, GOODMAN Z, et al.Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis:CENTAUR Phase 2b study design[J].Contemp Clin Trials, 2016, 47:356-365.
|
|
[35]SANYAL AJ, RATZIU V, HARRISON SH, et al.Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis:results from the year 1 primary analysis of the Phase 2b CENTAUR study[EB/OL] (2016-12) [2017-09].https://www.aasld.org/sites/default/files/LBA%20Full%20Abstracts%20Final%20 (Trimmed) .pdf.
|
|
[36]BRENNER C, GALLUZZI L, KEPP O, et al.Decoding cell death signals in liver inflammation[J].J Hepatol, 2013, 59 (3) :583-594.
|
|
[37]KARNIK S, CHARLTON MR, LI L, et al.Efficacy of an ASK1 inhibitor to reduce fibrosis and steatosis in a murine model of NASH is associated with normalization of lipids and hepatic gene expression and a reduction in serum biomarkers of inflammation and fibrosis[EB/OL]. (2015-11) [2017-09].http://liverlearning.aasld.org/aasld/2015/thelivermeeting/110603/satyajit.karnik.efficacy.of.an.ask1.inhibitor.to.reduce.fibrosis.and.steatosis.html.
|
|
[38]LOOMBA R, MANTRY PS, JAYAKUMAR S, et al.GS-4997, an inhibitor of apoptosis signal-regulating kinase (ASK1) , alone or in combination with simtuzumab for the treatment of nonalcoholic steatohepatitis (NASH) :a randomized, phase 2 trial[EB/OL]. (2016-11) [2017-09].http://natap.org/2016/AASLD/AASLD_68.htm.
|
|
[39]ADAR T, BEN YA'ACOV A, LALAZAR G, et al.Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells[J].Clin Exp Immunol, 2012, 167 (2) :252-260.
|
|
[40]MIZRAHI M, SHABAT Y, BEN YA'ACOV A, et al.Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin:results of a phase I/II clinical trial in NASH[J].J Inflamm Res, 2012, 5:141-150.
|
|
[41]ZHU L, BAKER SS, GILL C, et al.Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients:a connection between endogenous alcohol and NASH[J].Hepatology, 2013, 57 (2) :601-609.
|
|
[42]LOOMBA R, SEGURITAN V, LI W, et al.Gut microbiomebased metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease[J].Cell Metab, 2017, 25 (5) :1054-1062.
|
|
[43]FINNEY J, MOON HJ, RONNEBAUM T, et al.Human copperdependent amine oxidases[J].Arch Biochem Biophys, 2014, 546 (2) :19-32.
|
|
[44]JAROLIMEK W, BUSON A, CAO L, et al.Inhibition of lysyl oxidase like 2 reduces collagenaccumulation and collagen cross-links in CCl4-induced liver fibrosis[EB/OL]. (2016-02) [2017-09].http://www.pharmaxis.com.au/assets/Documents/pdf/02016/2016-02-11-Abstract-Keystone-2016.pdf
|
|
[45]PENG H, HE Y, ZHENG G, et al.Meta-analysis of traditional herbal medicine in the treatment of nonalcoholic fatty liver disease[J].Cell Mol Biol (Noisy-le-grand) , 2016, 62 (4) :88-95.
|
|
[46]LIU ZL, XIE LZ, ZHU J, et al.Herbal medicines for fatty liver dis eases[J].Cochrane Database Syst Rev, 2013, 8 (8) :CD009059.
|
|
[47]NIU XY, ZHAO WX.Review of traditional Chinese medicine treatment on nonalcoholic fatty liver disease[J].Tradit Chin Med Res, 2016, 29 (1) :75-78. (in Chinese) 牛逍遥, 赵文霞.非酒精性脂肪性肝病中医研究进展[J].中医研究, 2016, 29 (1) :75-78.
|
|
[48]LI HQ, SU SH, SONG J.Review of Chinese and western medicine treatment on nonalcoholic fatty liver disease[J].Clin Focus (Med J) , 2016, 31 (9) :1042-1044. (in Chinese) 李慧卿, 苏少慧, 宋娟.非酒精性脂肪肝中西医治疗新进展[J].临床荟萃, 2016, 31 (9) :1042-1044.
|
|
[49]LIU C, LIAO JZ, LI PY.Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease[J].World J Gastroenterol, 2017, 23 (11) :1964-1973.
|
|
[50]RAMOS-LEVI AM, RUBIO MA.Comment on rubino et al.Metabolic surgery in the treatment algorithm for type 2 diabetes:a Joint statement by international diabetes organizations.Diabetes Care2016;39:861-877[J].Diabetes Care, 2017, 40 (7) :e90-e91.
|
|
[51]KASAMA K, MUI W, WEI JL, et al.IFSO-APC consensus statements 2011[J].Obes Surg, 2012, 22 (5) :677-684.
|
|
[52]LASSAILLY G, CAIAZZO R, BUOB D, et al.Bariatric surgery reduces features of non-alcoholic steatohepatitis in morbidly obese patients[J].Gastroenterology, 2015, 149 (2) :379-388.
|
|
[53]AGUILAROLIVOS NE, ALMEDAVALDES P, AGUILARSALI-NAS CA, et al.The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome[J].Metabolism, 2016, 65 (8) :1196-1207.
|
|
[54]CLANTON J, SUBICHIN M.The effects of metabolic surgery on fatty liver disease and nonalcoholic steatohepatitis[J].Surg Clin North Am, 2016, 96 (4) :703-715.
|
|
[55]HAFEEZ S, AHMED MH.Bariatric surgery as potential treatment for nonalcoholic fatty liver disease:a future treatment by choice or by chance?[J].J Obes, 2013, 2013 (7) :839275.
|
DownLoad: